Glenmark Life Sciences Ltd

Glenmark Life Sciences Ltd

₹ 888 -0.28%
27 Feb 4:01 p.m.
About

Glenmark Life Sciences, a subsidiary of Glenmark Pharmaceuticals Ltd, is one of the leading developers and manufacturers of select high-value Active Pharmaceutical Ingredients. The company further operates in Contract Development and manufacturing operations to offer services to specialty Pharmaceutical companies.[1]

Key Points

Change in Ownership[1]
Co. was a subsidiary of Glenmark Pharmaceutical Ltd (GPL) and GPL has entered into a definitive agreement with Nirma. As per the agreement, GPL would sell 75% of its equity stake in GLS for INR56.5 billion. Post-transaction, GPL would own a 7.84% stake in GLS. The transaction is likely to close by the end of FY24.

  • Market Cap 10,877 Cr.
  • Current Price 888
  • High / Low 906 / 370
  • Stock P/E 21.0
  • Book Value 195
  • Dividend Yield 2.58 %
  • ROCE 29.9 %
  • ROE 22.3 %
  • Face Value 2.00

Pros

  • Company is almost debt free.
  • Company has a good return on equity (ROE) track record: 3 Years ROE 30.4%
  • Company has been maintaining a healthy dividend payout of 57.2%

Cons

  • Working capital days have increased from 112 days to 175 days

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
500 467 525 562 522 514 490 509 541 621 578 595 573
345 297 364 394 376 372 343 366 395 415 385 428 400
Operating Profit 155 170 160 167 146 142 147 144 145 206 193 167 173
OPM % 31% 36% 31% 30% 28% 28% 30% 28% 27% 33% 33% 28% 30%
0 0 4 2 4 5 9 10 7 3 2 5 2
Interest 22 21 21 7 0 0 0 0 0 0 0 0 0
Depreciation 8 8 9 10 10 10 10 10 11 12 13 13 13
Profit before tax 125 141 135 153 140 138 146 144 141 198 182 159 161
Tax % 25% 26% 25% 24% 26% 28% 26% 26% 26% 26% 26% 25% 26%
93 105 101 115 104 99 109 107 105 146 135 119 119
EPS in Rs 476.30 106.81 9.36 9.40 8.46 8.07 8.87 8.72 8.57 11.95 11.05 9.69 9.69
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 TTM
0 886 1,537 1,885 2,123 2,161 2,368
0 638 1,064 1,294 1,506 1,518 1,629
Operating Profit -0 248 473 592 617 643 739
OPM % -4% 28% 31% 31% 29% 30% 31%
0 -0 11 0 14 28 12
Interest 0 1 34 88 28 1 1
Depreciation 0 19 29 33 38 42 50
Profit before tax -0 228 421 471 565 629 699
Tax % -4,200% 14% 26% 25% 26% 26%
-0 196 313 352 419 467 519
EPS in Rs -430.00 997.86 1,597.37 358.74 34.17 38.11 42.38
Dividend Payout % 0% 0% 0% 0% 61% 110%
Compounded Sales Growth
10 Years: %
5 Years: 513%
3 Years: 12%
TTM: 15%
Compounded Profit Growth
10 Years: %
5 Years: 305%
3 Years: 14%
TTM: 24%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: 138%
Return on Equity
10 Years: %
5 Years: 40%
3 Years: 30%
Last Year: 22%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Sep 2023
Equity Capital 0 2 2 2 25 25 25
Reserves -1 86 400 751 2,030 2,114 2,367
0 0 0 0 3 19 18
1 1,387 1,324 1,244 414 545 543
Total Liabilities 0 1,475 1,726 1,997 2,471 2,702 2,953
0 456 546 573 590 781 783
CWIP 0 80 11 14 97 62 78
Investments 0 0 0 0 0 0 0
0 939 1,169 1,410 1,784 1,860 2,092
Total Assets 0 1,475 1,726 1,997 2,471 2,702 2,953

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
-0 10 195 388 598 313
0 -9 -51 -69 -122 -154
0 1 -137 -214 -79 -388
Net Cash Flow 0 2 8 106 397 -228

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Debtor Days 44 185 152 120 116 136
Inventory Days 162 441 227 214 185 224
Days Payable 41 201 111 92 110 147
Cash Conversion Cycle 165 424 268 241 190 213
Working Capital Days -2,059 -186 -37 12 150 175
ROCE % 529% 186% 97% 42% 30%

Shareholding Pattern

Numbers in percentages

1 Recently
Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023
82.84% 82.85% 82.85% 82.85% 82.85% 82.85% 82.85% 82.85% 82.85% 82.85%
8.03% 8.32% 8.12% 7.58% 6.04% 4.45% 3.28% 3.27% 4.39% 4.57%
0.46% 0.47% 0.56% 0.79% 0.79% 0.08% 0.00% 0.58% 0.64% 0.74%
8.67% 8.36% 8.47% 8.78% 10.31% 12.62% 13.86% 13.30% 12.13% 11.84%
No. of Shareholders 2,80,3002,53,7262,38,5782,33,5382,32,2032,25,7302,22,8662,08,2671,98,7641,85,531

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Concalls